Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults

Episode 2,   Jul 16, 05:53 PM

Episode image
To view the article and to claim credit for completing this CE activity, please CLICK HERE

Respiratory syncytial virus (RSV) is a common virus that primarily presents as upper respiratory infection but can develop in a significant number of patients as lower respiratory tract illness with complications including hospitalization and death. The risk of RSV complications is increased in adults aged 50 years and older, and without an FDA-approved treatment for RSV, pharmacists should advise patients of supportive care and prevention strategies including vaccination. This article will review clinical safety and efficacy data of RSV vaccine candidates currently in development for the older adult population. Factors contributing to disparities in adult vaccination rates and the role of the pharmacist in sharing evidence-based information about emerging vaccines and providing counseling and education to address barriers to vaccination will also be examined through patient counseling video vignettes. This article is additionally available as a recorded audiobook.